Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CH505 TF chTrimer Vaccine in Healthy Adults
NCT04915768Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jan 2023
- Primary completion
- Jul 2025
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of CH505 TF chTrimer + ALFQ in human immunodeficiency virus infection (HIV) (4 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Number of Participants Reporting Local Reactogenicity Events Signs and Symptoms: Erythema and/or Induration, Number of Participants Reporting Local Reactogenicity Events Signs and Symptoms: Pain and/or Tenderness and 9 more. Started Jan 2023; status: completed.
02
Drugs
CH505 TF chTrimer + ALFQ
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT04915768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04915768.